A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.
暂无分享,去创建一个
R. Sainson | A. Thotakura | Simon J. Henderson | Kerstin Pryke | E. Oelmann | S. Quaratino | N. Brennan | A. Newton